A novel algorithm for analyzing drug-drug interactions from MEDLINE literature

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Lu, Yin ^a   Shen, Dan ^b   Pietsch, Maxwell ^c   Nagar, Chetan ^a   Fadli, Zayd ^d   Huang, Hong ^b   Tu, Yi Cheng ^c   Cheng, Feng ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c University of South Florida   (United States)

^d SYRIAN PRIVATE UNIVERSITY   (Syrian Arab Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME; FUROSEMIDE; IBUPROFEN; SERTRALINE; WARFARIN;

ALGORITHM; CONTRAINDICATIONS; DRUG INTERACTION; HUMAN; HYDROLYSIS; MEDLINE; METABOLISM; STATISTICS AND NUMERICAL DATA;

ALGORITHMS; DRUG INTERACTIONS; ENZYMES; FUROSEMIDE; HUMANS; HYDROLYSIS; IBUPROFEN; MEDLINE; SERTRALINE; WARFARIN;

EID: 84948671877     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep17357     Document Type: Article

References (40)

1. Linda Brewer, D. W. Drug interactions that matter. Clinical pharmacology 40, 371-375 (2012).
2. Writers, A. M. Drug interactions result from a number of underlying pharmacokinetic and pharmacodynamic mechanisms. Drugs & Therapy Perspectives 29, 217-222 (2013).
3. Zhang, L., Reynolds, K. S., Zhao, P. & Huang, S. M. Drug interactions evaluation: an integrated part of risk assessment of therapeutics. Toxicology and applied pharmacology 243, 134-145, doi: 10. 1016/j. taap. 2009. 12. 016 (2010).
4. Percha, B. & Altman, R. B. Informatics confronts drug-drug interactions. Trends in pharmacological sciences 34, 178-184, doi: 10. 1016/j. tips. 2013. 01. 006 (2013).
5. Jankel, C. A. & Fitterman, L. K. Epidemiology of drug-drug interactions as a cause of hospital admissions. Drug safety 9, 51-59 (1993).
6. Leape, L. L. et al. Systems analysis of adverse drug events. ADE Prevention Study Group. Jama 274, 35-43 (1995).
7. Corrigan, O. P. A risky business: the detection of adverse drug reactions in clinical trials and post-marketing exercises. Social science & medicine 55, 497-507 (2002).
8. Huang, S. M. et al. New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. Journal of clinical pharmacology 48, 662-670, doi: 10. 1177/0091270007312153 (2008).
9. Quinney, S. K. et al. Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin. Drug metabolism and disposition: the biological fate of chemicals 38, 241-248, doi: 10. 1124/dmd. 109. 028746 (2010).
10. Schelleman, H. et al. Warfarin with fluoroquinolones, sulfonamides, or azole antifungals: interactions and the risk of hospitalization for gastrointestinal bleeding. Clinical pharmacology and therapeutics 84, 581-588, doi: 10. 1038/clpt. 2008. 150 (2008).
11. Vilar, S. et al. Drug-drug interaction through molecular structure similarity analysis. Journal of the American Medical Informatics Association: JAMIA 19, 1066-1074, doi: 10. 1136/amiajnl-2012-000935 (2012).
12. Vilar, S., Uriarte, E., Santana, L., Tatonetti, N. P. & Friedman, C. Detection of drug-drug interactions by modeling interaction profile fingerprints. PloS one 8, e58321, doi: 10. 1371/journal. pone. 0058321 (2013).
13. Keiser, M. J. et al. Predicting new molecular targets for known drugs. Nature 462, 175-181, doi: 10. 1038/nature08506 (2009).
14. Yildirim, M. A., Goh, K. I., Cusick, M. E., Barabasi, A. L. & Vidal, M. Drug-target network. Nature biotechnology 25, 1119-1126, doi: 10. 1038/nbt1338 (2007).
15. Berger, S. I. & Iyengar, R. Network analyses in systems pharmacology. Bioinformatics 25, 2466-2472, doi: 10. 1093/bioinformatics/ btp465 (2009).
16. Campillos, M., Kuhn, M., Gavin, A. C., Jensen, L. J. & Bork, P. Drug target identification using side-effect similarity. Science 321, 263-266, doi: 10. 1126/science. 1158140 (2008).
17. Lamb, J. et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313, 1929-1935, doi: 10. 1126/science. 1132939 (2006).
18. Tari, L., Anwar, S., Liang, S., Cai, J. & Baral, C. Discovering drug-drug interactions: a text-mining and reasoning approach based on properties of drug metabolism. Bioinformatics 26, i547-553, doi: 10. 1093/bioinformatics/btq382 (2010).
19. Percha, B., Garten, Y. & Altman, R. B. Discovery and explanation of drug-drug interactions via text mining. Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing, 410-421 (2012).
20. Segura-Bedmar, I., Martinez, P. & de Pablo-Sanchez, C. A linguistic rule-based approach to extract drug-drug interactions from pharmacological documents. BMC bioinformatics 12 Suppl 2, S1, doi: 10. 1186/1471-2105-12-S2-S1 (2011).
21. Yan, S., Jiang, X. & Chen, Y. Text Mining Driven Drug-Drug Interaction Detection. Proceedings. IEEE International Conference on Bioinformatics and Biomedicine, 349-355, doi: 10. 1109/BIBM. 2013. 6732517 (2013).
22. Wang, Z. et al. Literature mining on pharmacokinetics numerical data: a feasibility study. Journal of biomedical informatics 42, 726-735, doi: 10. 1016/j. jbi. 2009. 03. 010 (2009).
23. Duke, J. D. et al. Literature based drug interaction prediction with clinical assessment using electronic medical records: novel myopathy associated drug interactions. PLoS computational biology 8, e1002614, doi: 10. 1371/journal. pcbi. 1002614 (2012).
24. Tatonetti, N. P., Ye, P. P., Daneshjou, R. & Altman, R. B. Data-driven prediction of drug effects and interactions. Science translational medicine 4, 125ra131, doi: 10. 1126/scitranslmed. 3003377 (2012).
25. Hamman, M. A., Thompson, G. A. & Hall, S. D. Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C. Biochemical pharmacology 54, 33-41 (1997).
26. Hynninen, V. V. et al. Effects of the antifungals voriconazole and fluconazole on the pharmacokinetics of s-(+)-and R-()-Ibuprofen. Antimicrobial agents and chemotherapy 50, 1967-1972, doi: 10. 1128/AAC. 01483-05 (2006).
27. Warner, T. D. et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proceedings of the National Academy of Sciences of the United States of America 96, 7563-7568 (1999).
28. Havrda, D. E., Mai, T. & Chonlahan, J. Enhanced antithrombotic effect of warfarin associated with low-dose alcohol consumption. Pharmacotherapy 25, 303-307, doi: 10. 1592/phco. 25. 2. 303. 56955 (2005).
29. Greenblatt, D. J. & von Moltke, L. L. Interaction of warfarin with drugs, natural substances, and foods. Journal of clinical pharmacology 45, 127-132, doi: 10. 1177/0091270004271404 (2005).
30. Sanderson, S., Emery, J. & Higgins, J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genetics in medicine: official journal of the American College of Medical Genetics 7, 97-104, doi: 10. 109701. GIM. 0000153664. 65759. CF (2005).
31. Yin, T. & Miyata, T. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1-rationale and perspectives. Thrombosis research 120, 1-10, doi: 10. 1016/j. thromres. 2006. 10. 021 (2007).
32. Ageno, W. et al. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141, e44S-88S, doi: 10. 1378/chest. 11-2292 (2012).
33. Wilson, T. W., Badahman, A. H. & Kaushal, R. D. Thromboxane synthase inhibition enhances furosemide-induced renal vasodilation. Clin Invest Med 16, 372-378 (1993).
34. Lubelska, K. et al. Interactions between drugs and sulforaphane modulate the drug metabolism enzymatic system. Pharmacol Rep 64, 1243-1252 (2012).
35. Obach, R. S., Cox, L. M. & Tremaine, L. M. Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug metabolism and disposition: the biological fate of chemicals 33, 262-270, doi: 10. 1124/dmd. 104. 002428 (2005).
36. Preskorn, S. H., Alderman, J., Greenblatt, D. J. & Horst, W. D. Sertraline does not inhibit cytochrome P450 3A-mediated drug metabolism in vivo. Psychopharmacol Bull 33, 659-665 (1997).
37. Horowitz, B. Z. & Mullins, M. E. Cyproheptadine for serotonin syndrome in an accidental pediatric sertraline ingestion. Pediatr Emerg Care 15, 325-327 (1999).
38. Sayal, K. S., Duncan-McConnell, D. A., McConnell, H. W. & Taylor, D. M. Psychotropic interactions with warfarin. Acta psychiatrica Scandinavica 102, 250-255 (2000).
39. Hardy, H., Backman, E. S. & Farber, H. W. Successful bosentan and nonnucleoside reverse transcriptase inhibitor-based therapy in a patient with acquired immunodeficiency syndrome and pulmonary arterial hypertension. Pharmacotherapy 30, 139e-144e, doi: 10. 1592/phco. 30. 4. 422 (2010).
40. Newman, M. E. J. The Structure and Function of Complex Networks. SIAM Rev. 45, 167-256 (2003).